Novel Benzylidene Thiazolidinedione Derivatives as Partial PPAR gamma Agonists and their Antidiabetic Effects on Type 2 Diabetes

Creative Commons License

Yasmin S., Capone F., Laghezza A., Dal Piaz F., Loiodice F., Vijayan V., ...More

SCIENTIFIC REPORTS, vol.7, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 7
  • Publication Date: 2017
  • Doi Number: 10.1038/s41598-017-14776-0
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anadolu University Affiliated: Yes


Peroxisome proliferator-activated receptor gamma (PPAR gamma) has received significant attention as a key regulator of glucose and lipid homeostasis. In this study, we synthesized and tested a library of novel 5-benzylidene-thiazolidin-2,4-dione (BTZD) derivatives bearing a substituent on nitrogen of TZD nucleus (compounds 1a-1k, 2i-10i, 3a, 6a, and 8a-10a). Three compounds (1a, 1i, and 3a) exhibited selectivity towards PPAR. and were found to be weak to moderate partial agonists. Surface Plasmon Resonance (SPR) results demonstrated binding affinity of 1a, 1i and 3a towards PPAR gamma. Furthermore, docking experiments revealed that BTZDs interact with PPAR gamma through a distinct binding mode, forming primarily hydrophobic contacts with the ligand-binding pocket (LBD) without direct H-bonding interactions to key residues in H12 that are characteristic of full agonists. In addition, 1a, 1i and 3a significantly improved hyperglycemia and hyperlipidaemia in streptozotocin-nicotinamide (STZ-NA)-induced diabetic rats at a dose of 36 mg/kg/day administered orally for 15 days. Histopathological investigations revealed that microscopic architecture of pancreatic and hepatic cells improved in BTZDs-treated diabetic rats. These findings suggested that 1a, 1i and 3a are very promising pharmacological agents by selectively targeting PPAR. for further development in the clinical treatment of type 2 diabetes mellitus.